Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hengrui Acquires Rights to Novaliq Dry Eye Treatments in $165 Million Deal

publication date: Nov 11, 2019

Jiangsu Hengrui Medicine entered a $165 million agreement to in-license China rights for two dry eye treatments from Germany's Novaliq. Hengrui, which will pay $9 million upfront and up to $156 million in milestones, will develop, manufacture and commercialize the innovative, water-free drugs NOV03 and CyclASol® for greater China. Both drugs are in late stage US clinical trials. Novaliq says they have shown superior efficacy, with an early onset of action, excellent tolerability and better benefit-risk profiles than existing dry eye treatments. More details....

Stock Symbol: (SHA: 600276)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.